New Strategies in Neurogenic Heterotopic Ossification

Ampadiotaki, Margarita-Michaela; Evangelopoulos, Dimitrios Stergios; Pallis, Dimitrios; Vlachos, Christos; Vlamis, John; Evangelopoulos, Maria-Eleftheria

doi:10.7759/cureus.14709

Cited by 4 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditional treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and radiation therapy, but these have had limited use in children due to drug toxicity and potential radiation damage. Several treatments have recently emerged, including bisphosphonates, BMP inhibitors, and RARy agonists, but there is a lack of research specifically in children [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Heterotopic ossification of the elbow joint in a child: Successful surgical resection - A case report

Zhao,

2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Heterotopic ossification of the elbow joint in a child: Successful surgical resection - A case report

Zhao,

2024

Heliyon

View full text Add to dashboard Cite

“…At present, the treatment methods of heterotopic ossification include drug therapy, radiotherapy, surgery, rehabilitation therapy, etc. (17).…”

Section: Discussionmentioning

confidence: 99%

A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification

et al. 2022

View full text Add to dashboard Cite

Heterotopic ossification (HO) occurs when bone forms within non-ossifying tissues, such as in muscle. Palovarotene, an activator of retinoic acid receptor γ (RAR-γ), has been shown to inhibit the formation of ectopic bone in HO model mice, but its specific mechanism of action remains unclear. This study will explore the target and molecular mechanism of Palovarotene's action on HO by network pharmacology study. We collected the relevant targets of Palovarotene and HO from the database, obtained the potential targets of Palovarotene acting on HO through Venn analysis, and constructed the protein-protein interaction (PPI) network. Then, Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment Analysis and Module-based Network Analysis were performed for potential targets, and in addition, PPI Network Topology Analysis and Gene-Phenotype Correlation Analysis were performed. The results suggested that MAPK1, MDM2, and other targets as well as P53 signaling pathway and PI3K–Akt signaling pathway may be closely related to Palovarotene treatment of HO. We carried out verification experiments to confirm our finding, alkaline phosphatase and alizarin red staining in vitro and Micro-CT as well as hematoxylin-eosin staining in vivo were performed to verify treatment for HO of Palovarotene, reverse transcription polymerase chain reaction was also used to explore the transcription changes of MAPK1, MDM2, and osteogenic genes. This study systematically elucidated the possible mechanism of Palovarotene in the treatment of HO through network pharmacology study, revealing a new direction for the further application of Palovarotene in the treatment of HO.

show abstract

“…This leads to the proliferation of fibroadipogenic progenitors (FAPs) within the injured periarticular muscles and their subsequent osteogenic differentiation. FAPs are derived from mesenchyme [ 9 ] and can differentiate into chondrocytes, osteoblasts, or adipocytes [ 33 ]. Hypoxia appears to be one of the main factors contributing to a conducive environment.…”

Section: Reviewmentioning

confidence: 99%

Effectiveness of Prophylactic Interventions in Neurogenic Heterotopic Ossification (NHO): A Systematic Review

Rizvi¹,

Sharaf²,

Williams³

et al. 2022

Cureus

View full text Add to dashboard Cite

Neurogenic heterotopic ossification (NHO) is the formation of mature lamellar bone in peri-articular tissues following a neurological insult, most commonly traumatic brain injury (TBI) or spinal cord injury (SCI). NHO is a debilitating condition associated with significant morbidity and reduced quality of life. However, its pathophysiology remains poorly understood. While surgery is the mainstay of treatment once NHO has been diagnosed, prophylactic options are limited and not well studied. This review aimed to determine the efficacy of various interventions used in the primary prevention of NHO. We conducted an electronic literature search using five databases (PubMed, Embase, ScienceDirect, Cochrane Library, and Cumulative Index to Nursing and Allied Health Literature (CINAHL)) for records published until April 10, 2022. We identified 2,610 potentially eligible records across all databases. Nine reports met our eligibility criteria and were included in this review. Four were clinical trials (three randomized control trials, one nonrandomized trial), four were observational studies, and one was a systematic review/meta-analysis. The medications/interventions used included: warfarin, pulse low-intensity electromagnetic field therapy (PLIMF), bisphosphonates, and nonsteroidal anti-inflammatory drugs (NSAIDs). We did not find conclusive evidence to recommend the use of bisphosphonates and warfarin in the prevention of NHO. On the contrary, we found NSAIDs and PLIMF as effective prophylactic options based on the results of high-quality randomized control trials. Further prospective randomized studies with prolonged follow-ups are needed to confirm the long-term efficacy of these preventive interventions.

show abstract

New Strategies in Neurogenic Heterotopic Ossification

Cited by 4 publications

References 47 publications

Heterotopic ossification of the elbow joint in a child: Successful surgical resection - A case report

Heterotopic ossification of the elbow joint in a child: Successful surgical resection - A case report

A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification

Effectiveness of Prophylactic Interventions in Neurogenic Heterotopic Ossification (NHO): A Systematic Review

Contact Info

Product

Resources

About